Drugs in development · updated 9 November 2026
UMEC: clinical trials and development status
Other names and codes: GSK573719, Incruse Ellipta, Rolufta Ellipta (previously Rolufta), Incruse Ellipta (previously Incruse)
As of 9 November 2026 UMEC is in 4 active clinical trials (recruiting or ongoing, phases I–III) for 3 diseases. The most advanced phase is III.
Summary updated every week · data as of 9 November 2026. In Phuturdex you can follow UMEC and get an email at every change or safety alert.
Sign in free →What it is
The bromide salt form of umeclidinium, a muscarinic receptor antagonist, with bronchodilator activity. Although it does not display selectivity for specific muscarinic receptors, on topical application, umeclidinium acts mainly on M3 muscarinic receptors located on smooth muscle cells, thereby preventing smooth muscle contraction and resulting in bronchodilatory effect.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Asthma | III | 3 | NCT05757102 |
| Chronic obstructive pulmonary disease | III | 1 | NCT04536675 |
| Non-small-cell lung carcinoma | III | 1 | NCT04536675 |
Everything on UMEC
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 9 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.